STAT+: J&J spends $1 billion to enter KRAS race for cancer treatments
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Johnson & Johnson will acquire Firefly Bio for $1 billion to expand its KRAS inhibitor pipeline.
- Firefly Bio focuses on KRAS‑targeted drug development, a protein chemists have likened to a “greasy ball.”
- Revolution Medicines recently showed a KRAS‑targeted therapy nearly doubled survival in metastatic pancreatic cancer.
Why it matters: J&J secures a direct pipeline into KRAS‑targeted oncology, a market where recent data showed dramatic survival gains, positioning the company ahead of rivals while investors watch the $1 billion spend.
Ask SkimNews
